To evaluate the perceived state of health (PSH)of renal transplant N = 359). METHODS: The differences in PSH according to sex are presented here for patients included to date at all centres in the study. The analysis corresponds to the base moment, when they are on the transplant waiting list. A generic PSH profile, the SF-36 Health Questionnaire and an index, EQ-5D are applied to each patient. To evaluate the differences with respect to sex in both measurements, the Student-t test was used for independent samples and the chi-squared test for contingency tables. RESULTS: For the whole sample, the PCS score was 42.09 8.6, MCS 46.6 11.5 and VAS 60.1 17.4. Females had worse PSH than males on 7 of 8 dimensions of SF-36 (the exception being Social Functioning) and in the two summary scores: PCS (40.2 9.1 in females, 43.3 8 in males) and MCS (44.9 11.7 vs. 47.7 11.2) (p < 0.05). With regard to EQ-5D, females showed a similar score to males in VAS (58.2 18.1 vs. 61.4 16.9), but poorer scores in 4 of the 5 dimensions (except in personal care): mobility (p = 0.047), everyday tasks (p = 0.0001) and anxietydepression (p = 0.006). The PSH of patients of both sexes on renal transplant waiting lists at the centres studied is worse than that to be expected in the general population as regards physical health (score under 45 points), but similar as regards mental health (score over 45 points). VAS does not appear to be a good measurement of PSH as it oversimplifies, including as it does physical and mental aspects in a single index. CONCLUSIONS: Among these patients, the PSH of females is clearly worse than that of males, as is also the case in the general population, demonstrating the need for standardisation with respect to sex of scores on PSH questionnaires.
PUK22 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE
Caron M 1 , Emery MP 2 , Acquadro C 3 , Marquis P 4 , Piault E 4 1 Mapi Reserach Trust, Lyon, France, 2 Mapi Research Trust, Lyon, France, 3 Mapi Resaerch Institute, Lyon, France, 4 MAPI VALUES USA, Boston, MA, USA OBJECTIVES: Compare the PRO endpoints used in the approval of medicinal products for urinary incontinence, which led to a PRO labeling claim, with those recommended by the EMEA note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence (CPMP/EWP/18/01 final). METHODS: The PROLabels database is a unique on-line tool which collects information on the medicinal products for which the FDA and/or the EMEA have granted a PRO labeling claim. Using this database we searched the products with a urinary incontinence indication, and approved by the European Commission through the centralized procedure. For each drug, we analyzed the endpoints used in the clinical studies to assess treatment efficacy. These endpoints were then compared to those recommended by the CPMP guidance for the treatment of urinary incontinence. RESULTS: Three products have been retrieved, for which a marketing authorization in Europe to treat urinary incontinence was granted; all of which have been approved between June and October 2004. For the three products, the clinical outcomes measures used for evaluation included subjective outcome measures and quantification of symptoms (i.e. diaries and quality of life instruments), in accordance with the CPMP guidance. Only pad weighing tests were not used in these studies. In all 3 cases, quantification of symptoms resulted in a PRO claim. Quality of life assessment generated a labeling claim for two products, and subjective outcomes (global improvement) for one. CONCLUSIONS: In the evaluation of medicinal products for urinary incontinence, there is a close adherence to the guidance concerning the choice of study endpoints, with different rates of success concerning the PRO claims obtained. The PROLabels database has proven its usefulness in retrieving the PRO endpoints used in clinical studies for products approval in a specific indication and in comparison to the guidance. To evaluate the impact of overactive bladder (OAB) on the frequency of sexual activity and sexual enjoyment in women. METHODS: A population-based telephone survey was conducted in Sweden, Italy, Germany, the UK, and Canada to evaluate the prevalence and burden of OAB symptoms using current International Continence Society definitions. A nested case-control analysis was performed on data collected from women with OAB (cases, n = 995) and without OAB (controls, n = 1524). Survey respondents reported whether they experienced a decrease in sexual activity or enjoyment of sex owing to urinary symptoms and whether they had physician-diagnosed depression. Factors influencing sexual activity and sexual satisfaction were analyzed using logistic regression. RESULTS: Among participants aged ≤50 and >50 years the following reported being sexually active during the past 12 months, respectively: 78% and 41% of controls, 74% and 36% of cases without incontinence, and 74% and 35% of cases with incontinence. Cases were significantly more likely to report decreased sexual activity caused by urinary symptoms than were controls among respondents aged ≤50 (odds ratio [OR] = 4.3, 95% confidence interval [CI] = 2.4-7.7) and those aged >50 years (OR = 2.6, 95% CI = 1.2-5.2), after controlling for incontinence and depression. Among sexually active participants (n = 1420), OAB cases were significantly more likely to report decreased sexual enjoyment due to urinary symptoms than were controls (≤50 y: OR = 5.8, 95% CI = 3.0-11.4; >50 y: OR = 3.1, 95% CI = 1.1-8.9). CONCLUSIONS: This is the first multinational, population-based study to assess the impact of OAB on sexual activity and enjoyment in women. Women with OAB were significantly more likely than were controls to report decreased sexual activity and enjoyment due to urinary symptoms, even after adjusting for incontinence and depression. The impact of OAB on sexual activity and enjoyment appeared greatest in younger women (≤50 years of age).
